The Big Data Steering Group set up by EMA and the Heads of Medicines Agencies (HMA) has published its   third workplan that sets key actions to be delivered between 2022–25.

The new workplan will allow to further enhance the efficient integration of data analysis into the evaluation of medicinal products by regulators. Using novel technologies and the evidence generated from big data will benefit public health by accelerating medicine development, improving treatment outcomes and facilitating earlier patient access to new treatments.